<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009226</url>
  </required_header>
  <id_info>
    <org_study_id>13/NE/0123</org_study_id>
    <nct_id>NCT04009226</nct_id>
  </id_info>
  <brief_title>International GNE Myopathy Patient Registry</brief_title>
  <official_title>International GNE Myopathy Patient Registry (GNE001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Newcastle University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GNE myopathy, an ultra-rare disease, is a severe progressive myopathy that typically presents&#xD;
      in early adulthood as weakness in the distal muscles of the lower extremities and progresses&#xD;
      proximally, leading to a loss of muscle strength and function, and ultimately a&#xD;
      wheelchair-bound state. The rate of progression is gradual and variable over the course of&#xD;
      10-20 years or longer.&#xD;
&#xD;
      There is a need to understand the world wide epidemiology of this ultra-rare condition,&#xD;
      better understand a long-term disease course and the progression of disease-specific&#xD;
      features, support translational research by evaluating burden illness and support clinical&#xD;
      research recruitment. Therefore, the study will longitudinally collect information via an&#xD;
      online patient registry platform.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GNE myopathy is an ultra- rare condition. Most of the knowledge is coming from case reports&#xD;
      or small cohort observations. There is a need to more precisely understand the long-term&#xD;
      disease course and the progression of disease-specific features of GNE myopathy, and in turn&#xD;
      characterise the overall burden of this illness. Also, to better understand the disease,&#xD;
      describe it variability, genotype-phenotype correlation, quality of life, epidemiology,&#xD;
      health-economics aspects and need for assistive walking devices. Collected data needs to be&#xD;
      harmonised to be compatible collaborative work with Remudy (Japanese patient registry). This&#xD;
      collaborative effort will enable the analysis of the largest GNE myopathy data set in the&#xD;
      world. To this end, this study will collect patient information longitudinally. Upon&#xD;
      patient's agreement, the registry curator can contact nominated clinicians to request&#xD;
      additional data or data validation.&#xD;
&#xD;
      Study Objectives&#xD;
&#xD;
      The objectives of the study are to:&#xD;
&#xD;
        -  Longitudinally characterize disease-specific features of GNE myopathy&#xD;
&#xD;
        -  Characterize the burden of illness and quality of life in patients with GNE myopathy&#xD;
&#xD;
        -  Support recruitment in research activities&#xD;
&#xD;
        -  Inform registry participants via newsletters about scientific developments in the GNE&#xD;
           myopathy field&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Disease history</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported disease history including GNE myopathy diagnosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General medical history</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported general medical history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication use</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported medical use.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life questionnaire (non-validated)</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of physical activity</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported level of physical activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle biopsy and genetic testing status</measure>
    <time_frame>12 months</time_frame>
    <description>Patient reported history of muscle biopsy and details of whether they have undergone genetic testing for GNE myopathy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">430</enrollment>
  <condition>GNE Myopathy</condition>
  <condition>Hereditary Inclusion Body Myopathy</condition>
  <arm_group>
    <arm_group_label>Participants with GNE</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Registry</intervention_name>
    <description>Participants who have volunteered to participate will complete various questionnaires relating to their condition.</description>
    <arm_group_label>Participants with GNE</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Must have a diagnosis of GNE myopathy (also known as HIBM, Quadriceps Sparing Myopathy&#xD;
        (QSM), Inclusion Body Myopathy Type 2, distal myopathy with rimmed vacuoles (DMRV), or&#xD;
        Nonaka disease)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older at the time of informed consent&#xD;
&#xD;
          -  Clinical and/or genetic diagnosis of GNE myopathy (also known as HIBM, QSM, Inclusion&#xD;
             Body Myopathy Type 2, DMRV, or Nonaka disease)&#xD;
&#xD;
          -  Willing and able to provided electronic (or written) consent and comply with all study&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Straub, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Walton Muscular Dystrophy Research Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Registry Curator</last_name>
    <phone>0191 2418605</phone>
    <email>lucy.imber@newcastle.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Walton Muscular Dystrophy Research Centre</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Registry Curator</last_name>
      <phone>0191 2418605</phone>
      <email>lucy.imber@newcastle.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Volker Straub, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Distal Myopathies</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <keyword>Muscular Dystrophies</keyword>
  <keyword>GNE Myopathy</keyword>
  <keyword>Hereditary Inclusion Body Myopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Distal Myopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

